Brief: Valeo Pharma Amends Agreement With Novartis Pharmaceuticals Canada

Valeo Pharma

02/02/2024 22:26

Feb 2 (Reuters) - Valeo Pharma Inc  VPH.TO :
    * VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS
PHARMACEUTICALS
CANADA FOR (PR)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD
HEALTHCARE ROYALTY PARTNERS, LP
    * VALEO PHARMA INC - PROCEEDS FROM REIMBURSEMENT TO BE USED
FOR
DEBT REDUCTION PURPOSES
    * VALEO PHARMA INC - SIMBRINZA REMAINS UNDER VALEO PHARMA
EXCLUSIVE PROMOTION AND DISTRIBUTION
    * VALEO PHARMA INC - WILL CONTINUE TO DISTRIBUTE XIIDRA FOR
ENTIRE
TRANSITION PERIOD
    * VALEO PHARMA INC - TRANSITION PERIOD IS EXPECTED TO
CONTINUE
UNTIL APPROXIMATELY Q3-2024
    * VALEO PHARMA INC - SAGARD CREDIT FACILITY AMENDED TO
PROVIDE FOR
EARLY REPAYMENTS AND LIQUIDITY REQUIREMENTS IN FISCAL 2024
    * VALEO PHARMA- TO CONTINUE TO COMMERCIALIZE AND PROMOTE
SIMBRINZA
ON EXCLUSIVE BASIS AS PROVIDED BY COMMERCIAL AND SUPPLY
AGREEMENT WITH NOVARTIS
    * VALEO PHARMA: TO CONTINUE TO DISTRIBUTE XIIDRA FOR ENTIRE
TRANSITION PERIOD, UNTIL CERTAIN REGULATORY TRANSFERS RECEIVED
BY XIIDRA GLOBAL PURCHASER

Source text for Eikon:  ID:nCNWGW4f4a 
Further company coverage:  VPH.TO 

 ((Reuters.Briefs@thomsonreuters.com;))